Asymptomatic neuroendocrine tumor of the ileocecal area in a 59 year-old patient – a case study
DOI:
https://doi.org/10.15584/medrev.2016.1.9Keywords:
neuroendocrine tumor, neuroendocrine tumor of the small intestine, chromogranin AAbstract
One of the more common locations of neuroendocrine tumors (Neuroendocrine Tumors, NET) of the gastrointestinal tract is the small intestine. In the majority of cases, these are slow to develop, highly differentiated tumors, which pose a diagnostic challenge to gastroenterologists, radiologists and pathologists. From the clinical viewpoint, NETs of the small intestine may be hormonally inactive or produce substances responsible for the occurrence of characteristic clinical symptoms. The serum concentration of chromogranin A is a sensitive, yet nonspecific, marker of such changes. The basic method of diagnosing is through the use of imaging techniques, which allow for the location of the tumor; and endoscopic techniques, which permit the extraction of a tissue sample for histopathology and immunohistochemistry ancillary tests. Surgical excision of a lesion is the treatment of choice. However, if pharmacotherapy is employed, the somatostatin analogs, radioisotope therapy and chemotherapy is used. We present a case study, of an asymptomatic neuroendocrine tumor of the ileocecal area, in a 59 year-old male patient.
Downloads
References
Kaltas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Rev 2004;25:458-511.
Salazar R, Wiedenmann B, Rindi G, Ruszniewski P. ENETS 2011 consensus guidelines for the management of patients Wit didestive neuroendocrine tumors: an update. Neuroendocrinology 2012;95:71-73.
Bolanowski M. Guzy neuroendokrynne jelita cienkiego. Zespół rakowiaka. W: Hollek-Roszak O, Ruzicka M. Guzy neuroendokrynne układu pokarmowego, Wydawnictwo Via Medica, Gdańsk 2010,191-207.
Hubalewska-Dydejczyk A, Stefańska A. Leczenie chorych na nowotwory neuroendokrynne przewodu pokarmowego. MP Chirurgia 2012;4:63-65.
Kos-Kudła B, Bolanowski M, Handkiewicz-Junak D i wsp. Zalecenia diagnostyczno-lecznicze w guzach neuroendokrynnych układu pokarmowego (rekomendowane przez Polska Sieć Guzów Neuroendokrynnych). Endokrynol Pol 2008;59:41-56.
Bolanowski M, Kos-Kudła B. Możliwości rozpoznawania i leczenia guzów neuroendokrynnych przewodu pokarmowego. Post Hig Med Dośw 2005;59:48-55.
Kos-Kudła B, Zemczak A. Współczesne metody rozpoznawania i leczenia guzów neuroendokrynnych układu pokarmowego. Endokrynol Pol 2006;2:174-186.
O’Toole D, Grossman A, Gross D et al. ENTETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. Neuroendocrinology 2009;90:194-202.
Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001;12: 69-72.
Ferrari L, Seregni E, Bajetta E et al. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. Anticancer Res 1999; 19:3415-3427.
Bellutti M, Fry LC. Detection of Neuroendocrine Tumors of the Small Bowel by Double Ballon Endoscopy. Dig Dis Sci 2009;54:1050-1058.
Stijn JB, van Weyenberg MD, Martijn R et al. MR Enteroclysis in the diagnosis of small-bowel neoplasms. Radiology 2010;254:765-773.
Masselli G, Colaiacomo MC, Marcelli G et al. MRI of the small-bowel: how to differentiate primary neoplasms and mimickers. Br J Radiol 2012; 85:824-837.
Plockinger U, Wiedenmann B. Diagnosis of non-functioning neuro-endocrine gastro-enteropancreatic tumours. Neuroendocrinology 2004; 80:35-38.
Soreide JA, van Heerden JA, Thompson GB et al. Gastrointestinal carcinoid tumors: Long -term prognosis for surgically treated patients. World J Surg 2000;24:1431-1436.
Makridis Ch, Öberg K, Juhlin C et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990;14:377-385.
Panzuto F, Nasoni S, Falconi N et al. Prognosis factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-1092.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Medical Review
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
